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Abstract
Primary membranous nephropathy is associated with increased risk of venous thromboembolic
events, which are inversely correlated with serum albumin levels. To evaluate the potential benefit
of prophylactic anticoagulation (venous thromboembolic events prevented) relative to the risk
(major bleeds), we constructed a Markov decision model. The venous thromboembolic event risk
according to serum albumin was obtained from an inception cohort of 898 patients with primary
membranous nephropathy. Risk estimates of hemorrhage were obtained from a systematic
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literature review. Benefit-to-risk ratios were predicted according to bleeding risk and serum
albumin. This ratio increased with worsening hypoalbuminemia from 4.5:1 for an albumin under 3
g/dl to 13.1:1 for an albumin under 2 g/dl in patients at low bleeding risk. Patients at intermediate
bleeding risk with an albumin under 2 g/dl have a moderately favorable benefit-to-risk ratio (under
5:1). Patients at high bleeding risk are unlikely to benefit from prophylactic anticoagulation
regardless of albuminemia. Probabilistic sensitivity analysis, to account for uncertainty in risk
estimates, confirmed these trends. From these data, we constructed a tool to estimate the
likelihood of benefit based on an individual’s bleeding risk profile, serum albumin level, and
acceptable benefit-to-risk ratio (http://www.gntools.com). This tool provides an approach to the
decision of prophylactic anticoagulation personalized to the individual’s needs and adaptable to
dynamic changes in health status and risk profile.
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The nephrotic syndrome, characterized by proteinuria, edema, hyperlipidemia, and
hypoalbuminemia,1 is associated with an increased risk of venous thromboembolic events
(VTEs) such as deep vein or renal vein thrombosis, and pulmonary embolism.2–6 The risk of
VTEs is particularly high in patients with primary membranous nephropathy when
compared with other nephrotic diseases.7,8 Among patients with primary membranous
nephropathy, hypoalbuminemia is the most important independent risk factor for VTEs. On
the basis of the largest cohort of patients with membranous nephropathy studied to date, we
have recently demonstrated that the risk of VTEs increases incrementally when serum
albumin levels fall below 2.8 g/dl.9 Proteinuria was not an independent risk factor of VTEs.
The risk of VTEs varies over time, in parallel with changes in serum albumin.
These findings beg the important question of the utility of prophylactic anticoagulation in
patients with membranous nephropathy. There is currently no evidence-based guide for the
use of prophylactic anticoagulation tailored to an individual’s risks of VTEs and bleeding
from anticoagulation.
We developed a tool that aids in deciding whether to use prophylactic anticoagulation in
patients with primary membranous nephropathy. We generated a user-friendly computer
program that provides the likelihood of benefit from prophylactic anticoagulation based on
an individual patient’s risk of VTEs, bleeding risk profile, and the physician’s and patient’s
threshold of tolerance to trade-off the risk of major bleeding to prevent a VTE. Our model
incorporates new data on risk estimates of clinically apparent VTEs based on levels of
hypoalbuminemia (the most powerful predictor risk of VTEs9) as well as data regarding the
graded risk of major bleeding from warfarin anticoagulation. The risk estimates of VTEs
were derived from longitudinal clinical data on 539 patients from an inception cohort of 898
patients with biopsy-proven primary membranous nephropathy.9 As there are no published
data regarding bleeding in patients with the nephrotic syndrome treated with warfarin, the
graded risk of bleeding was derived from the Anticoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) study, a large population-based cohort study of warfarin prophylactic
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anticoagulation, with target international normalized ratio (INR) of 2–3.10 We verified that
the incidence of major bleeds among warfarin-treated patients with glomerulonephritis and
hypoalbuminemia from our own registries was within the range reported by the ATRIA
study. After calculating base benefit-to-risk ratios, we performed probabilistic sensitivity
analysis to account for variability surrounding model inputs.
Our analysis suggests that the benefit-to-risk ratio favors prophylactic anticoagulation in
patients at low risk of bleeding, but not in those at high risk of bleeding. Our study uses new
real-world clinical data to establish a personalized, easily applicable clinical tool to inform
decisions regarding prophylactic anticoagulation in primary membranous nephropathy.
RESULTS
Model construction
We constructed a hybrid Markov decision tree model to predict the benefit-to-risk ratio
associated with prophylactic anticoagulation (VTEs prevented:major bleed incurred). The
decision model, including major decision and end point nodes, is illustrated in Figure 1.
To construct this model, we used actual observed VTE rates derived from a large patient
cohort. No patient received prophylactic anticoagulation. Table 1 summarizes the
characteristics of the cohort from which risk estimates of clinically apparent VTEs were
derived. For each threshold of serum albumin, the incidence of VTEs was calculated by the
number of events during the total period at risk. The period at risk was defined as the time
spent at or below the corresponding level of serum albumin.
Table 2 provides the decision input data for the two clinical approaches—prophylactic
anticoagulation versus observation— including the incidence rates and corresponding
probabilities for pertinent clinical outcomes, major bleeds based on risk score categories,
and VTEs during periods of hypoalbuminemia below each specified threshold. These
thresholds were previously correlated with incremental increases in the risk of VTEs.9 Major
bleeds were defined as involving vital organs or requiring transfusion of ≥2 units of packed
red blood cells.10 For our model, we adopted the low (≤3 points), intermediate (4 points),
and high (5–10 points) bleeding risk categories described in the ATRIA study.10 We also
calculated the incidence of major bleed in a cohort of 98 warfarin-treated patients with
glomerulonephritis, a median serum albumin 2.1 g/dl (interquartile range 1.7–2.6) and a
total warfarin exposure of 207.4 person-years (Table 3). Sixty-five percent had a low, 10%
intermediate, and 25% high bleeding score. The annual incidence of bleed was 0.4 events
per 100 patient-year of anticoagulation (95% confidence interval: 0.01–2.69), which is in the
range reported in the ATRIA study for patients in the low-to-intermediate bleeding risk
categories (Table 2).
Predicted benefit-to-risk ratios
The results of the base–case analysis of benefit-to-risk ratio (ratio of the number of VTEs
prevented divided by major bleeds incurred) for each category of serum albumin and
bleeding risk are provided in Table 4. For patients at low risk of major bleed (ATRIA score
≤3 points) and serum albumin <3.0 g/dl, the base–case model predicts that 4.5 VTEs will be
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prevented at the cost of one major bleed during 24 months of prophylactic anticoagulation
(benefit-to-risk ratio = 4.5:1). The benefit-to-risk ratio increases incrementally with
worsening hypoalbuminemia to 5.2:1 for serum albumin <2.8 g/dl, and to 13.1:1 for serum
albumin <2.0 g/dl. For each level of hypoalbuminemia, the benefit-to-risk ratio is lower for
patients with intermediate bleeding risk (ATRIA score 4) compared with patients at low risk
of bleeding, and increases incrementally from 1.3:1 (for serum albumin <3.0 g/dl) to 3.9:1
(for serum albumin <2.0 g/dl). For patients in the high bleeding-risk category (ATRIA score
5–10), the benefit-to-risk ratio remains below 2:1 even for the most profound
hypoalbuminemia level.
Consideration of uncertainty: probabilistic sensitivity analysis
Probabilistic sensitivity analysis was conducted to evaluate the impact of uncertainty
surrounding the risk and event estimates used in the Markov model. The Monte Carlo
simulation presents various possible scenarios considering plausible ranges of model inputs.
Figure 2 is a graphic representation of the range in benefit-to-risk derived from the Markov
model while randomly varying the input estimates. Each simulated plot represents a range of
the number of VTEs prevented (horizontal axis) and major bleeding events incurred (vertical
axis) according to bleeding risk and the degree of hypoalbuminemia. Reference benefit-to-
risk ratios that clinicians and patients may consider as thresholds for decision-making (from
upper to lower, 2:1, 5:1, and 10:1, respectively) are provided.
For patients in the high bleeding-risk category (open circles), the density plots aggregate
entirely above the 2:1 benefit-to-risk line when the albumin is <3.0 g/dl (Figure 2a),
indicating that fewer than two VTEs would be prevented with prophylactic anticoagulation
for each major bleed incurred. Indeed in the high bleeding-risk category, the results fall
above the 2:1 acceptability threshold line regardless of whether the albumin is <3.0 mg/dl
(Figure 2a), <2.5 mg/dl (Figure 2b), or <2.0 mg/dl (Figure 2c), suggesting a uniformly
unacceptable benefit-to-risk ratio.
In contrast, for patients in the low bleeding-risk category, (open triangles) the vast majority
of simulated results aggregate below and to the right of the 5:1 acceptability threshold when
the serum albumin is <2.5 or <2.0 mg/dl (Figure 2b and c). In this setting, five or more
VTEs would be prevented for one bleed incurred. Furthermore, for serum albumin level
<2.0 g/dl, most of the density plot for the low bleeding-risk category falls to the right and
below the 10:1 acceptability threshold (Figure 2c), indicating an even higher benefit-to-risk
ratio.
Adaptation for a clinical decision tool
The data from the probabilistic sensitivity analysis were adapted to provide the likelihood of
benefit from prophylactic anticoagulation based on each individual’s bleeding-risk category,
serum albumin, and risk tolerance. For each bleeding-risk category (Figure 3a–c), the
benefit-to-risk acceptability curves summarize graphically the probability of clinical benefit
from prophylactic anticoagulation compared with observation (y axis) given a physician and
patient’s willingness to accept the trade-off for the risk of major bleeding to prevent VTEs
(x axis). The probability of net benefit varies according to the level of serum albumin
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(curves), and can therefore be re-evaluated during the evolving course of a patient’s disease.
Figure 3a is applicable to patients at low bleeding risk. Accepting a 5:1 benefit-torisk ratio
(5 VTEs–prevented for 1 bleed incurred) (x axis), the likelihood of benefit from
prophylactic anticoagulation would be 480% with serum albumin <2.5 g/dl(–○–) but <50%
with serum albumin <2.8 g/dl (–□–). Applying the more stringent threshold of 10:1, the
likelihood of benefit for patients with serum albumin <2.0 g/dl (–◊–) would be 72%. Patients
in the intermediate bleeding risk category and a serum albumin <2.0 g/dl would have a
likelihood of benefit from prophylactic anticoagulation <15% when accepting a 5:1 benefit-
to-risk ratio, but >67% for a 3:1 ratio (Figure 3b). For patients in the high bleeding-risk
category, the benefit-to-risk ratio does not favor anticoagulation, with a likelihood of benefit
<1% even with serum albumin <2.0 g/dl (Figure 3c).
DISCUSSION
The frequency of VTEs in patients with nephrotic syndrome is higher than in the general
population,11,12 and is higher in patients with membranous nephropathy compared with
other proteinuric kidney diseases.7,8,13 Limited data exist to guide the decision on
prophylactic anticoagulation at the individual patient level, balancing the potential benefits
and risks, with consideration of evolving disease activity. Several studies have firmly linked
the risk of VTEs with the severity of hypoalbuminemia.9,14 Although no publications
specifically address the complication rate of anticoagulation in patients with nephrotic
syndrome, several have identified risk factors for bleeding in the setting of prophylactic
anticoagulation with warfarin for atrial fibrillation,10,15,16 and can be reasonably applied to
patients with membranous nephropathy. In our study, we have incorporated these new data
to weigh the relative benefits and risks of prophylactic warfarin anticoagulation based on
individual patients’ clinical characteristics.
The results of our decision analysis indicate that for patients at low bleeding risk (ATRIA
risk score 0–3 out of 10), the benefit-to-risk ratio favors prophylactic anticoagulation at low
serum albumin levels. For patients at intermediate risk of bleeding (risk score of 4),
prophylactic anticoagulation may be favorable with severe hypoalbuminemia (<2 g/dl),
while accepting lower benefit-to-risk ratio (<5:1). Thus, for patients at low or intermediate
bleeding risk, the threshold serum albumin level below which anticoagulation is favored
depends on the patient’s and physician’s ‘trade-off ’ acceptability of bleeding risk. In
contrast, for patients at high risk of bleeding (risk scores 5–10), the benefit-to-risk ratio does
not favor prophylactic anticoagulation even with severe hypoalbuminemia (<2.0 g/dl). We
therefore propose that the decision of prophylactic anticoagulation in patients with primary
membranous nephropathy should start with an assessment of a patient’s bleeding risk
(Figure 4). For patients determined to be at low or intermediate risk of bleeding, the next
step is to ‘look’ at the serum albumin concentration and ‘choose’ the preferred benefit-to-
risk ratio. These parameters are then used to determine the probability of benefit of
prophylactic anticoagulation.
Our findings offer important advantages over the previous decision analysis.17 Our study
uses the ratio of VTEs prevented to bleeds incurred as the main outcome of interest, thus
offering flexibility in choosing the strategy based on an individualized acceptability of
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benefit-to-risk ratio. Because we base risk assessment of VTEs on serum albumin level, our
approach allows for a dynamic re-evaluation of benefit and risk as the patient’s albumin
level changes with time or in response to treatment. Likewise, assessment of bleeding risk is
also dynamic based on changes in the patient’s risk factors (e.g., a decrease in renal
function, or development of hypertension). Changes in risks of VTEs and bleeding also can
be used to discontinue anticoagulation once the risk of VTEs decreases or that of bleeding
increases. The longitudinal data from our large inception cohort allowed us to measure the
incidence of VTEs based on the period at risk of each patient for the determined level of
hypoalbuminemia, rather than the total time of follow-up. This approach provides a more
accurate risk estimate of VTEs than data derived from small cohort studies that did not take
into account this period at risk. Likewise, our study uses a stratified risk of bleeding from
anticoagulation as described in the ATRIA study. The large size of the ATRIA study cohort
provides an accurate estimate of bleeding risk and detailed incidence rates for the various
risk categories. This study also provided an easily applicable scoring system for bleeding
risk stratification. Importantly, the confidence intervals of the bleeding risks reported in the
ATRIA study encompass those reported in other studies of prophylactic anticoagulation for
atrial fibrillation (Supplementary Appendix 7 online). Therefore, using the sensitivity
analysis, the benefit-to-risk ratios we report for each level of bleeding risk category also
reflect those we would have obtained using other bleeding-score models.
Despite differences in demographics and comorbidities between the ATRIA study cohort
and ours, the risk factors for major bleeding of warfarin identified by the ATRIA study
should also apply to patients with primary membranous nephropathy, as the very large
ATRIA cohort (13,559 patients) encompasses the range of age and glomerular filtration rate
of our cohort. Further, the bleeding risk in our model is estimated for each patient
individually, and is therefore not affected by overall demographic differences between the
ATRIA and membranous nephropathy cohorts.
As to the important question of whether patients with hypoalbuminemia have a greater risk
of bleeding than reported in the ATRIA study, there are little data published regarding the
relationship between serum albumin and risk of anticoagulation with coumadin.
Hypoalbuminemia may affect the pharmacokinetics of coumadin18,19 and increase the risk
of overanticoagulation,20,21 and hypoalbuminemia has been associated with a higher risk of
minor but not major hemorrhages in one study.22 We analyzed data from our own registries
regarding 98 warfarin-treated patients with primary glomerulonephritis and coexistent
hypoalbuminemia. We found an incidence rate of major bleeding well within the range
predicted by ATRIA for patients at low risk of bleeding. Nevertheless, we recognize that the
bleeding rates from the ATRIA study should be used cautiously when extrapolating to
different populations.
There are limitations to our analysis. Because our VTE incidence is derived retrospectively
from clinically apparent events in our cohort, our incidence data may be an underestimation
of the true VTE risk. However, a recent large prospective randomized controlled trial in
patients with membranous nephropathy reported a frequency of clinically apparent VTEs of
7.5%23 similar to that observed in our own cohort, thus providing reassurance that we did
not underestimate the risk of VTEs. The case fatality rates were drawn from population data,
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and extrapolation to patients with idiopathic membranous nephropathy should also be
carried out with caution. There are other known risk factors for VTEs that were not
incorporated in our original analysis of VTEs for lack of sufficient data (e.g.,
immobilization, smoking, morbid obesity, heart failure, and genetic propensity). The
presence of such additional factors should be taken into account by the treating physician in
assessing the benefit-to-risk of prophylactic anticoagulation for an individual patient. Our
results have not been prospectively tested, and therefore are not directly clinically validated.
Finally, the results of our model are specific to primary membranous nephropathy and the
benefit-to-risk ratios for each level of hypoalbuminemia cannot be directly applied to other
forms of nephrotic syndrome associated with lower rates of VTEs.7,8 Adapting our model to
other forms of nephrotic syndrome (e.g., focal segmental glomerulosclerosis) will require
separate in-depth analysis of VTE incidence by the level of hypoalbuminemia in patients
with these diseases. Further study is also required to assess the risk of bleeding in
hypoalbuminemic patients using warfarin or newer anticoagulation agents. Finally, future
research is needed to prospectively validate our proposed model for prophylactic
anticoagulation, ideally through a randomized controlled trial, but more realistically through
prospective follow-up of a multicenter registry of patients.
In summary, we propose a practical approach to the decision of prophylactic anticoagulation
in patients with primary membranous nephropathy based on an individual patient’s bleeding
risk, serum albumin concentration, and risk tolerance as reflected by the selected benefit-to
risk ratio (Figure 4). This model was adapted to a user-friendly online computerized
program (http://www.gntools.com). Our approach allows for a dynamic re-evaluation of the
net benefit of anticoagulation with changes in the clinical status of each patient and the risk
tolerance of the clinician and patient.
MATERIALS AND METHODS
A detailed description of the methods is available online in the Supplementary Appendix.
We built a hybrid Markov decision tree model for our decision analysis (Figure 1). Two
alternative therapeutic strategies were compared: (1) prophylactic anticoagulation with
warfarin (target INR 2–3) and (2) clinical observation and treatment of symptomatic VTEs.
A simulated cohort of 10,000 patients was assumed to enter the model. We used monthly
cycles over a 24-month time horizon to assess the relative benefit of anticoagulation
compared with clinical observation, balancing the risk of major bleeding against risk of
VTEs at various levels of hypoalbuminemia. Input data for the model shown in Table 2 were
derived from a large inception cohort of patients and a systematic review of the literature.
The analysis was run in two ways: base–case analysis using point estimates of input
variables and probabilistic sensitivity analysis with Monte Carlo simulation method.
Risk estimates for VTEs
To apply the VTE risk estimates in various hypoalbuminemia levels to the model, we
calculated the incidence rates of VTEs on 539 patients from an inception cohort of 898
patients with biopsyproven primary membranous nephropathy pooled from the University of
North Carolina and the University of Toronto (Table 1 and Supplementary Appendix 1
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online). Patients with underlying infection, cancer, autoimmune disease (other than
membranous nephropathy), prior history of VTEs, or known thrombotic propensity or
precipitating event (e.g., catheter) were excluded. The incidence rate of VTEs was
calculated as the total of new events divided by the sum of person time at risk: measured as
the duration of hypoalbuminemia with thresholds: <2.0, <2.3, <2.5, <2.8, and <3.0 g/dl. Our
previous analysis demonstrated an increased risk of VTEs below the threshold serum
albumin concentration of 2.8 g/dl.9
A systematic search was conducted to compare the incidence rates of VTEs derived from
our cohort to those in the published literature using PubMed, EMBASE, and Cochrane
Central Register of Controlled Trials databases as well as prior reviews24,25 and decision
analysis17 (Supplementary Appendices 2 and 3 online).
Risk estimates for major bleeding
Risk estimates for major bleeding from warfarin prophylactic anticoagulation would ideally
derive from patients with membranous nephropathy or nephrotic syndrome. An exhaustive
literature search revealed no published study reporting the risk of bleeding in these
populations (Supplementary Appendix 4 online). We therefore referred to the ATRIA
study,10,26,27 a large cohort study of prophylactic anticoagulation using warfarin in patients
with atrial fibrillation. That study defined major bleeding as major vital organ hemorrhage
including intracranial hemorrhage, retroperitoneal hemorrhage, or hemorrhage requiring
transfusion of ≥2 units of blood. The ATRIA risk score for major bleeding was derived by
multivariate regression model and based on anemia (hemoglobin 13 g/dl in men and <12
g/dl in women) (3 points), estimated glomerular filtration rate <30 ml/min per 1.73m2 (3
points),28 age ≥75 years (2 points), prior hemorrhage (1 point), and diagnosis of
hypertension (1 point). For our model, we adopted the three bleeding risk categories
described in the ATRIA study and their respective rates of major bleeding per 100 person-
years: low (0–3 points) 0.76; intermediate (4 points) 2.62; and high (5–10 points) 5.76.
To compare the ATRIA study’s estimated risks for major bleeding to those reported by
randomized controlled trials that used warfarin anticoagulation, we conducted a systematic
literature review (Supplementary Appendices 5–7 online). The reported incidence rates for
major hemorrhage (0.9–4.6 per 100 person-years) reported by other studies were within the
ranges used in the ATRIA study (0.7–6.6 per 100 person-years). These incidence rates are
therefore reflected in our sensitivity analyses.
To verify whether patients with nephrotic syndrome have a greater risk of hemorrhage with
warfarin anticoagulation, we analyzed the incidence of major bleeding in a separate cohort
of 98 patients with glomerulonephritis (membranous nephropathy 72%; focal segmental
glomerulosclerosis 25%, immunoglobulin A nephropathy 3%), and hypoalbuminemia (<3 g
per day). We compared the incidence of bleeding in this cohort to that predicted by the
ATRIA study, taking into accounts the bleeding risk score for each patient (Tables 2 and 3).
Input probabilities
Table 2 summarizes input variables and their ranges used in the model. All incidence rates
were converted to probabilities using the formula: probability = 1 − e(−rate×time).29 For the
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probabilities of VTEs at various serum albumin levels, we used our own cohort data. For
probabilities of major bleeding, we used the data from the ATRIA study. Case-fatality rates
of VTEs and major bleeding were obtained from a systematic review article,30 as no deaths
from these causes occurred in our cohort. The probabilities of death rate from other causes,
progression to end-stage renal disease, and recovery from nephrotic syndrome were derived
from our inception cohort data.
Incremental benefit-to-risk ratio
The model calculated the number of VTEs that would occur with (VTEon AC) and without
(VTEobs) prophylactic anticoagulation for 24 months. The number of major bleeds
(bleedon AC) was accumulated only for the prophylaxis strategy as the risk of spontaneous
severe hemorrhage (requiring blood transfusion) in the absence of anticoagulation is
exceedingly low. We presented the ratio of the number of VTEs prevented (incremental
benefit, ΔB: VTEon AC − VTEobs) to the number of major bleeds that would have occurred
with prophylaxis (incremental risk, ΔR: bleedon AC – 0) as a main outcome of interest.31 The
incremental benefit-to-risk ratio calculation was repeated for different levels of bleeding risk
and serum albumin concentration (<2.0, <2.3, <2.5, <2.8, and <3.0 g/dl).
Probabilistic sensitivity analysis
A point estimate of the benefit-to-risk ratio is insufficient to draw conclusions about the use
of prophylactic anticoagulation. To characterize the effect of the uncertainty of our model
inputs, we conducted a probabilistic sensitivity analysis whereby all model inputs are varied
simultaneously across appropriately defined distributions (Supplementary Appendix 8
online). Using a Monte Carlo simulation (with 1000 iterations),29 values of each model
input were selected randomly from the assigned distributions and the numbers of VTEs and
major bleeding events incurred were calculated for the prophylaxis and observation
strategies. The number of VTEs prevented and major bleeding events are displayed in a
scatter plot (Figure 2). The Monte Carlo simulation was repeated for each combination of
bleeding risk and serum albumin concentration.
Likelihood of net benefit
To present the simulation results in a manner to assist clinical decision-making, we adopted
the concept of net-benefit framework32 and used it to create benefit–risk acceptability
curves. For example, a benefit-to-risk trade-off ratio of 10:1 would accept 1 hemorrhage for
10 VTEs prevented. For each trade-off ratio, if the net benefit is >0, then prophylactic
anticoagulation offers a greater benefit than observation. For a range of trade-off values, the
curves represent the proportion of times that prophylaxis would be beneficial. This
probability was calculated for each combination of bleeding risk category and serum
albumin level.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hybrid Markov decision tree model
The square indicates a decision node in which the clinician may choose from either of two
alternatives—prophylactic anticoagulation or observation and treatment of clinically
apparent venous thromboembolic events (VTEs). The circles represent chance nodes in
which events occur at random (i.e., outside the clinician’s control). The letter M in a circle
represents a Markov node and the triangles represent terminal nodes or clinical end
outcomes. AC, anticoagulation; ESRD, end-stage renal disease; NS, nephrotic syndrome;
obs, observation; VTEobs, VTE occurring in the observation strategy; VTEon AC, VTE
occurring while on prophylactic anticoagulation; VTEoff AC, VTE occurring subsequent to a
major bleeding event.
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Figure 2. Consideration of uncertainty: probabilistic sensitivity analysis
Monte Carlo simulation plots of benefit and risk at various levels of hypoalbuminemia; plots
show the simulation results according to combinations of risk categories of major bleeding
in the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study10 and different
serum albumin levels: (a) <3.0 g/dl, (b) <2.5 g/dl, and (c) <2.0 g/dl. Each graph includes
three density plots representing high risk bleeding risk (upper, open circles), intermediate
bleeding risk (middle, open diamonds), and low bleeding risk (lower, open triangles),
respectively. Three benefit-to-risk threshold lines are shown for reference (2:1, 5:1, and
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10:1). Simulation points lying to the right and below the threshold lines indicate that the
benefit-to-risk ratio is larger than the threshold. For example, points lying below and to the
right of the ‘10:1 ratio’ line have benefit-to-risk ratios >10:1.
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Figure 3. Benefit–risk acceptability curves
Benefit–risk acceptability curves represent the probability (vertical axis) of prophylactic
anticoagulation being beneficial at various levels of the benefit-to-risk ratio (horizontal
axis). Major bleeding risk categories (low and intermediate) were derived from the ATRIA
study.10 Each curve corresponds to each serum albumin level (from top to bottom,<2.0 to
<3.0 g/dl, respectively). (a) Low risk of major bleeding, (b) intermediate risk of major
bleeding, and (c) high risk of major bleeding.
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Decision approach for prophylactic anticoagulation.
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Table 1
Characteristics of the inception cohort of patients with membranous nephropathy
Characteristic
Mean±s.d. median
(IQR), or n (%)
Total n 539
Baseline: at diagnosis
  Age (years) 49.2±16
  Sex, n (%)
    Male 340 (63.1)
    Female 199 (36.9)
  Race, n (%)
    White 360 (66.8)
    Black 66 (12.2)
    Others 72 (13.4)
    Unknown 41 (7.6)
Serum albumin (g/dl) 2.4±0.6
eGFR (ml/min per 1.73m2) 73.5±31.6
Proteinuria (g/24 h) 8.5±5.7
Treatment regimen
  No immunosuppression 170 (31.5)
  Corticosteroid alone 199 (36.9)
  Cyclophosphamide/CNI 170 (31.5)
Follow-up
  Observed incidence of VTE, n (%) 24 (100)
    DVT of lower extremities 6 (25)
    RVT 5 (21)
    PE (including combined with DVT or RVT) 11 (46)
    Others (subclavian vein and IVC) 2 (8)
  Observed incidence of VTE, number of events/person-year at riska
    Serum albumin <3.0 g/dl (n=539) 24/656.66
    Serum albumin <2.8 g/dl (n=483) 23/539.47
    Serum albumin <2.5 g/dl (n=381) 21/325.24
    Serum albumin <2.3 g/dl (n=221) 15/176.29
    Serum albumin <2.0 g/dl (n=169) 11/96.29
Abbreviations: CNI, calcineurin inhibitor; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; IQR, 25th to 75th percentile
interquartile range; IVC, inferior vena cava; PE, pulmonary thromboembolism; RVT, renal vein thrombosis; VTE, venous thromboembolism.
a
Person-year at risk represents the cumulative duration below the specified threshold of hypoalbuminemia.
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Table 2
Decision model input data for the different clinical approaches: prophylactic anticoagulation versus
observation
Parameters Annual incidence events/100 PY (95% CI) Monthly probability (ranges)
Death from other causes in NS 1.38 (0.63–2.62) 0.00115
Progression to ESRD 0.31 (0.04–1.11) 0.00025
Recovery from NS 60.16 (52.41–67.92) 0.0489
Active persistent NS 20.67 (16.12–25.21) 0.94969
Prophylactic anticoagulation
  Major bleedinga,10
    Low risk (score 0–3) 0.76 (0.66–0.87) 0.00063 (0.00055–0.00073)
    Intermediate risk (score 4) 2.62 (2.28–3.01) 0.00218 (0.00167–0.00279)
    High risk (score 5–10) 5.76 (5.01–6.61) 0.00479 (0.00415–0.00552)
  Death from major bleeding30 0.113
  Hazard ratio of VTE on anticoagulation 0.05 (0.01–0.37)
  VTEon ACb Calculated
  Death from VTEon AC30 0.137
  VTEoff AC Same as VTEobs
  Death from VTEoff AC30 0.137
Observation
  VTEobs serum albumin <3.0 g/dl 3.67 (2.35–5.46) 0.00306 (0.00196–0.00454)
  VTEobs serum albumin <2.8 g/dl 4.26 (2.70–6.40) 0.00355 (0.00225–0.00532)
  VTEobs serum albumin <2.5 g/dl 6.46 (4.00–9.87) 0.00537 (0.00333–0.00819)
  VTEobs serum albumin <2.3 g/dl 8.51 (4.96–13.62) 0.00707 (0.00412–0.01129)
  VTEobs serum albumin <2.0 g/dl 11.42 (5.70–20.44) 0.00948 (0.00474–0.01689)
  Death from VTEobs30 0.137
Abbreviations: AC, anticoagulation; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation study; CI, confidence interval; ESRD, end-
stage renal disease; NS, nephrotic syndrome; obs, observation; PY, person-year; VTE, venous thromboembolic event; VTEobs, VTE occurring in
the observation strategy; VTEon AC, VTE occurring while on prophylactic anticoagulation; VTEoff AC, VTE occurring subsequent to a major
bleeding event.
a
Bleeding risk categories as described in the ATRIA study. The ATRIA risk score is calculated based on the presence of the following factors:
anemia (3 points), severe renal disease (estimated GFR <30 ml/min per 1.73m2) (3 points); age ≥75 years (2 points); any prior hemorrhage (1
point); and diagnosed hypertension (1 point).
b
Incidence rate of VTEon AC=incidence rate of VTEobs×hazard ratio of VTE on anticoagulation.
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Table 3
Incidence of major bleeding in a cohort of 98 warfarin-treated patients with glomerulonephritis
Characteristic
Total n 98
Underlying disease, n (%)
  MN 71 (72)
  FSGS 3 (3)
  IgA nephropathy 25 (24)
Serum albumin level, median (IQR) (g/dl) 2.1 (1.7–2.6)
Concomitant drugs, n (%)
  ASA 23 (23)
  Steroids 85 (87)
ATRIA score, 0–10 2.5 (0–4)
ATRIA risk criteria, n (% of total exposure time)
  Low (0–3) 64 (70)
  Intermediate (4) 10 (9)
  High (5–10) 24 (21)
Total exposure time on warfarin (years) 207.42
Median time of exposure (IQR) (years) 1.43 (0.75–2.7)
Major bleeding event, n 1
Incidence, event/100 person-year (95% CI) 0.48 (0.01–2.69)
Abbreviations: ASA, aminosalicylic acid; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation study; CI, confidence interval; FSGS,
focal segmental glomerulosclerosis; IgA, immunoglobulin A; IQR, interquartile range; MN, membranous nephropathy.
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Table 4










<3.0 4.5 (378/84) 1.3 (378/286) 0.6 (377/614)
<2.8 5.2 (437/84) 1.5 (436/286) 0.7 (436/614)
<2.5 7.7 (650/84) 2.3 (649/286) 1.1 (648/614)
<2.3 10.0 (842/84) 2.9 (841/286) 1.4 (840/614)
<2.0 13.1 (1103/84) 3.9 (1103/286) 1.8 (1102/614)
Abbreviation: VTE, venous thromboembolic events. Numbers within parenthesis are numbers of VTE prevented/major bleeds incurred. Base–case
analysis was conducted by applying point estimates of parameters.
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